Effect of magnesium on Nephrotoxicity of Carboplatin

Kidney-protective Effect of Magnesium Supplementation in Carboplatin-containing Chemotherapy for Pediatric Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190619043948N1

Enrollment

Registered

2020-04-11

Start date

2019-11-06

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotoxicity of Carboplatin. Nephropathy induced by other drugs, medicaments and biological substances

Interventions

Intervention 1: Control group: Patients receive placebo tablet (Jalinus brand) orally for two weeks each day before Carboplatin therapy. Intervention 2: Intervention group: Patients receive magnesium

Eligibility

Sex/Gender

All

Age

2 Years to 16 Years

Inclusion criteria

Inclusion criteria: Children over 2 years of age with malignancy receiving Carboplatin

Exclusion criteria

Exclusion criteria: Kidney disorder with GFR under 30 Receiving other platinum drugs or other nephrotoxic drugs Receiving antibiotics

Design outcomes

Primary

Measure	Time frame
Blood urea nitrogen. Timepoint: Before intervention and 2 and 7 days later. Method of measurement: Mass spectrometry.;Creatinine. Timepoint: Before intervention and 3 and 7 days later. Method of measurement: Mass spectrometry.;Glomerular filtration rate. Timepoint: Before intervention and 3 and 7 days later. Method of measurement: Schwartz formula, by calculation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzie Alizade Hadadhania

Arak University of Medical Sciences

marzie.alizade@gmail.com+98 28 3333 7711

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026